FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

VaxGen sells anthrax vaccine to its old rival

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to $8 million in milestones.

VaxGen began to founder in 2006 when the government revoked an $877 million contract for the VaxGen vaccine after the company failed to start a human trial on schedule. Now Emergent, which makes the only FDA-approved anthrax vaccine now available, says it plans to advance the experimental vaccine.

VaxGen, which once had more than 200 employees, has been reduced to a staff of about six after a planned merger with Raven biotechnologies fell through.

- here's VaxGen's release on the deal

Related Articles:
Struggling VaxGen sells anthrax vaccine to rival
VaxGen faces possible liquidation after merger flops
Shareholders stymie VaxGen, Raven merger
Momentum builds for VaxGen, Raven merger
VaxGen slashes staff--again


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Vaccine   anthrax   VaxGen   Emergent BioSolutions